Cytos Biotechnology AG

DGAP-News: Cytos Biotechnology Ltd, Annual Shareholders' Meeting: Shareholders approved all proposals and resolutions. (with additional features)

EQS Group AG-News: Cytos Biotechnology AG / Key word(s): AGM/EGM
Cytos Biotechnology Ltd, Annual Shareholders' Meeting: Shareholders
approved all proposals and resolutions. (with additional features)

28.06.2013 / 19:00


Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders
approve all resolutions

Schlieren (Zurich), Switzerland, 28 June 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) today announced that its shareholders have approved all
resolutions at the Annual Shareholders' Meeting 2013.

The Annual Shareholders' Meeting of Cytos Biotechnology Ltd took place at
the company's headquarters in Schlieren (Zurich), Switzerland. It was
attended by 38 shareholders. 12,584,907 shares or 56.15% of a total of
22,411,431 shares were represented.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
first-in-class immune modulator in Phase 2 clinical development as a
potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to
selectively suppress the body's immune response to allergens, a predominant
risk factor for asthma. In a successfully completed Phase 2a study, CYT003
was shown to maintain asthma control and lung function in patients with
persistent allergic asthma, even as standard inhaled corticosteroid
treatment was withdrawn. CYT003 has been shown to be safe in over 450
patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of
Technology (ETH) in Zurich. It is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.

End of Corporate News

Additional features:


Document title: AGM


28.06.2013 This press release was distributed by EQS CORPORATE
COMMUNICATIONS. - news archive:

The issuer is responsible for the contents of the release.


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Freiverkehr in Berlin, München, Stuttgart; Frankfurt in
             Open Market ; SIX

End of News    EQS Group AG News-Service
218808 28.06.2013

Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: